Form 8-K - Current report
July 31 2023 - 5:20PM
Edgar (US Regulatory)
00-0000000 true false 0001613780 0001613780 2023-07-31 2023-07-31 0001613780 us-gaap:CommonStockMember 2023-07-31 2023-07-31 0001613780 dei:AdrMember 2023-07-31 2023-07-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
July 31, 2023
Date of Report (Date of earliest event reported)
DBV Technologies S.A.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
| France |
|
001-36697 |
|
Not applicable |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
|
177-181 avenue Pierre Brossolette 92120 Montrouge France |
|
Not Applicable |
| (Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: +33 1 55 42 78 78
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
| Ordinary shares, nominal value €0.10 per share |
|
n/a |
|
The Nasdaq Stock Market LLC* |
| American Depositary Shares, each representing one- half of one ordinary share, nominal value €0.10 per share |
|
DBVT |
|
The Nasdaq Stock Market LLC |
| * |
Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC. |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 |
Results of Operations and Financial Condition |
On July 31, 2023, DBV Technologies S.A. (the “Company”) issued a press release announcing financial results and business highlights for the fiscal quarter ended June 30, 2023. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item 9.01 |
Financial Statements and Exhibits |
(d) Exhibits
|
|
|
| Exhibit No. |
|
Description |
|
|
| 99.1 |
|
Press Release issued July 31, 2023 |
|
|
| 104 |
|
Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
| Date: July 31, 2023 |
|
DBV TECHNOLOGIES S.A. |
|
|
|
|
|
|
|
|
By: |
|
/s/ Sébastien Robitaille |
|
|
|
|
Name: Sébastien Robitaille |
|
|
|
|
Title: Chief Financial Officer |
Exhibit 99.1
|
|
|
| |
|
|
| |
|
|
|
|
|
Press Release
Montrouge, France, July 31,
2023 |
DBV
Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second
Quarter and Half-Year 2023 Financial Results
| |
● |
|
Received feedback from U.S. Food and Drug Administration (FDA) on DBV’s two
supplemental safety studies in toddlers (ages 1 – 3 years) and children (ages 4 – 7 years). |
| |
● |
|
The two Phase 3 pivotal safety studies will be named COMFORT Toddlers (1 – 3
years) and COMFORT Children (4 – 7 years). |
| |
● |
|
COMFORT Toddlers will be a 6-month safety
study, consistent with agreement previously reached with FDA on the COMFORT Children safety study. |
| |
● |
|
The Company expects to seek final alignment with FDA on the COMFORT protocols prior
to commencing the studies. |
| |
● |
|
DBV closes Q2 2023 with a cash balance of $174 million.
|
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a
clinical-stage biopharmaceutical company, today announced the receipt of Written Responses from the FDA on key study design elements for the COMFORT (Characterization of the Optimal Management of FOod Allergy
Relief and Treatment) Toddlers and COMFORT Children supplemental safety studies in 1 – 3-year-olds and 4 – 7-year-olds, respectively, with a
peanut allergy. The Company also reported financial results for the second quarter and the first half of 2023. The quarterly and half-year financial statements were approved by the Board of Directors on July 28, 2023.
Recent Business Developments
Viaskin™ Peanut in 1 – 3-year-olds
(original square patch) and Viaskin™ Peanut in 4 – 7-year-olds (modified circular patch) are separate product candidates with independent clinical
and regulatory paths supporting two distinct Biologics License Applications (BLAs).
DBV received Type C Meeting Written Responses from the FDA on the two supplemental safety
studies, known as COMFORT. The COMFORT Toddlers safety study will enroll peanut allergic toddlers ages 1 – 3-years and will support the efficacy results generated from the EPITOPE Phase 3 pivotal study.
The COMFORT Children safety study will enroll peanut allergic children ages 4 – 7-years and will support the efficacy results anticipated from the ongoing VITESSE Phase 3 pivotal study.
The FDA agreed with a 6-month study duration and a 3:1 randomization (active:placebo) of approximately
400 subjects in the double-blind, placebo-controlled COMFORT Toddlers study. Both COMFORT studies will assess adhesion using the same tools and measurements that were established in VITESSE. Neither the COMFORT Toddlers study nor the COMFORT
Children study will require an oral food challenge for participation.
The feedback received is consistent with FDA’s position on
COMFORT Children in 4 – 7-year-olds, as previously announced in December
2022.
Both COMFORT studies aim to bring the total number of subjects on
active treatment to approximately 600 participants in each age group, when added to their respective Phase 3 pivotal efficacy studies (i.e., EPITOPE and VITESSE).
“We are pleased to have received feedback from the FDA on key design elements for the COMFORT safety study protocols in 1 – 3 and
4 – 7-year-olds with peanut allergy,” said Daniel Tassé, Chief Executive Officer, DBV Technologies. “This continues the positive momentum DBV received in December 2022 and April 2023 when we outlined our regulatory pathways for Viaskin Peanut in children and
toddlers. We are actively enrolling subjects in the VITESSE Phase 3 study and were also honored to have our EPITOPE data published in the New England Journal of Medicine in May, with
an accompanying editorial. The COMFORT Toddlers and COMFORT Children safety studies meet the FDA’s request for additional safety studies in these patient populations. As we complete the final protocols, which we expect to share with FDA, we are
actively progressing site selection and contracting to enable the start of the COMFORT safety studies as soon as final FDA protocol alignment is achieved.”
Conference Call
DBV
will host a conference call and live audio webcast on Monday, July 31st, at 5:00 p.m. ET to report first half 2023 financial results and provide a corporate update.
Participants may access this event via the below teleconferencing numbers and asking to join
the DBV Technologies call:
| |
• |
|
United States: 1-844-481-2866 |
| |
• |
|
International: +1-412-317-1859 |
A live webcast of the call will be available on the
Investors & Media section of the Company’s website:
https://www.dbv-technologies.com/investor-relations/. A replay of the
presentation will also be available on DBV’s website after the event.
Financial Highlights for the Second Quarter and the
Six Months Ended June 30, 2023
The Company’s interim consolidated financial statements for the six months ended
June 30, 2023, are prepared in accordance with both generally accepted accounting principles in the U.S. (“U.S. GAAP”) and International Financial Reporting Standards (“IFRS”) as adopted by the European Union. Unless
otherwise indicated, the financial figures presented in the Q2 Financial Highlights comply with both U.S. GAAP and IFRS consolidated financial statements. The financial figures are commented for the six months ended June 30, 2023, under U.S.
GAAP. Differences between U.S. GAAP and IFRS consolidated financial statements are mainly due to discrepancies arising from the application of lease accounting standards.
Cash and Cash Equivalents
|
|
|
|
|
|
|
|
|
| |
|
|
| (in millions of USD) |
|
U.S. GAAP |
|
IFRS |
| |
Six months ended June 30,
|
|
Six months ended June 30,
|
| |
2023 |
|
2022 |
|
2023 |
|
2022 |
| |
|
|
|
|
|
Net cash & cash equivalents at the beginning of the period |
|
209.2 |
|
77.3 |
|
209.2 |
|
77.3 |
| |
|
|
|
|
|
Net cash flow used in operating activities |
|
(46.4) |
|
(11.7) |
|
(45.4) |
|
(8.6) |
| |
|
|
|
|
|
Net cash flow provided by / (used in) investing activities |
|
(0.3) |
|
(0.2) |
|
(0.3) |
|
(0.2) |
| |
|
|
|
|
|
Net cash flow provided by / ((used in) financing activities |
|
7.8 |
|
195.2 |
|
6.8 |
|
192.1 |
| |
|
|
|
|
|
Effect of exchange rate changes on cash & cash equivalents |
|
3.7 |
|
(12.6) |
|
3.7 |
|
(12.6) |
| |
|
|
|
|
|
Net cash & cash equivalents at the end of the period |
|
174.0 |
|
248.0 |
|
174.0 |
|
248.0 |
Cash and cash equivalents amount to $174.0 million as of June 30, 2023, compared to
$209.2 million as of December 31, 2022, which is a net decrease by $35.2 million mainly due to the following:
| |
(1) |
$46.4 million of cash used for operations, mainly driven by the initiation of the VITESSE trial with
the first patient screened in March 2023. |
Cash used for operations in the six months ended
June 30, 2023, increased by $34.7 million compared to the six months ended June 30, 2022. The Company received 24.8 million euros during the six months ended June 30, 2022, for reimbursement of 2019, 2020, and 2021 French
research tax credits.
| |
(2) |
$7.8 million proceeds from the issuance and sale of new ordinary shares in form of American Depositary
Shares (“ADSs”) on June 16, 2023, and pursuant to the At-The-Market (“ATM”) program established in May 2022. |
Cash provided by financing activities decreased by $187.4 million in the six months ended June 30, 2023, compared to
the six months ended June 30, 2022. The Company issued and sold new ordinary shares in form of ADSs for a total gross amount of $15.3 million in May 2022, and completed a private placement financing (“PIPE”) amounting to
$194.0 million gross in June 2022.
| |
(3) |
$3.7 million positive impact of changes in exchange rates. The Company’s treasury position, stated
in U.S. Dollars, has been impacted by an appreciation of Euro against U.S. Dollar during the six months ended June 30, 2023. |
Operating Income
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
| In millions of USD |
|
U.S. GAAP |
|
U.S. GAAP |
|
IFRS |
| |
Three months ended June 30,
|
|
Six months ended June 30,
|
|
Six months ended June 30,
|
| |
2023 |
|
2022 |
|
2023 |
|
2022 |
|
2023 |
|
2022 |
| |
|
|
|
|
|
|
|
Research tax credits |
|
2.0 |
|
1.5 |
|
3.7 |
|
3.1 |
|
3.7 |
|
3.1 |
| |
|
|
|
|
|
|
|
Other operating income |
|
0.3 |
|
- |
|
0.7 |
|
1.0 |
|
0.7 |
|
1.0 |
| |
|
|
|
|
|
|
|
Operating income |
|
2.3 |
|
1.5 |
|
4.4 |
|
4.1 |
|
4.4 |
|
4.1 |
Operating income amounts to $4.4 million for the six months ended June 30, 2023,
compared to $4.1 million for the six months ended June 30, 2022, which is an increase by $0.3 million due to:
| |
(1) |
$0.6 million increase in research tax credit estimate as costs eligible to the French tax credit
increased to support research and development activities (a) after the initiation of VITESSE with the first patient screened in March 2023, and (b) as part of the new safety study for toddlers after the FDA confirmed in April 2023
additional safety data is required for BLA submission. |
| |
(2) |
Partially offset by a decrease by $0.3 million in other operating income that consists of revenues
recognized in advance as part of the collaboration agreement with Nestlé Health Science (“NHS”). |
Operating Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
| In millions of USD |
|
U.S. GAAP |
|
U.S. GAAP |
|
IFRS |
| |
Three months ended June 30,
|
|
Six months ended June 30,
|
|
Six months ended June 30,
|
| |
2023 |
|
2022 |
|
2023 |
|
2022 |
|
2023 |
|
2022 |
| |
|
|
|
|
|
|
|
Research & Development |
|
17.6 |
|
18.6 |
|
33.6 |
|
30.8 |
|
33.5 |
|
30.7 |
| |
|
|
|
|
|
|
|
Sales & Marketing |
|
0.5 |
|
1.0 |
|
1.0 |
|
1.5 |
|
1.0 |
|
1.5 |
| |
|
|
|
|
|
|
|
General & Administrative |
|
9.2 |
|
5.7 |
|
16.1 |
|
12.3 |
|
16.2 |
|
12.2 |
| |
|
|
|
|
|
|
|
Operating expenses |
|
27.3 |
|
25.3 |
|
50.7 |
|
44.6 |
|
50.7 |
|
44.4 |
Operating expenses amount to $50.7 million for the six months ended June 30, 2023, compared to
$44.6 million for the six months ended June 30, 2022, which is an increase by $6.1 million mainly due to:
| |
(1) |
The increase by $2.8 million in research and development expenses mainly explained by the difference in
phasing of on-going clinical trials between the two compared periods, including initiation costs of the VITESSE trial with the first patient screened in March 2023. |
| |
(2) |
The increase by $3.8 million in general and administrative expenses mainly related to one-time costs associated with financing activities, organizational planning, market research and planning activities. |
| |
(3) |
Partially offset by the decrease by $0.5 million in sales and marketing expenses due to a decrease of
external professional services and employee-related costs. |
Net Loss and Net Loss Per Share
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
| |
|
U.S. GAAP |
|
U.S. GAAP |
|
IFRS |
| |
Three months ended June 30,
|
|
Six months ended June 30,
|
|
Six months ended June 30,
|
| |
2023 |
|
2022 |
|
2023 |
|
2022 |
|
2023 |
|
2022 |
| |
|
|
|
|
|
|
|
Net income / (loss) (in millions of USD) |
|
(24.2) |
|
(23.0) |
|
(44,8) |
|
(39.7) |
|
(44.9) |
|
(39.5) |
| |
|
|
|
|
|
|
|
Basic / diluted net income / (loss) per share (USD/share) |
|
(0.26) |
|
(0.35) |
|
(0.48) |
|
(0.66) |
|
(0.48) |
|
(0.65) |
Net result for the six months ended June 30, 2023, is a loss amounting to $44.8 million, compared to
a loss amounting to $39.7 million for the six months ended June 30, 2022.
On a per share basis, net loss (based on the weighted
average number of shares outstanding over the period) is $0.48 for the six months ended June 30, 2023.
CONDENSED CONSOLIDATED
STATEMENTS OF FINANCIAL POSITION (unaudited)
|
|
|
|
|
|
|
|
|
| In millions of USD |
|
U.S. GAAP |
|
IFRS |
| |
June 30, 2023
|
|
December 31, 2022
|
|
June 30, 2023
|
|
December
31, 2022 |
| |
|
|
|
|
|
Assets |
|
217.5 |
|
246.5 |
|
217.5 |
|
246.5 |
| |
|
|
|
|
|
of which cash & cash equivalents |
|
174.0 |
|
209.2 |
|
174.0 |
|
209.2 |
| |
|
|
|
|
|
Liabilities |
|
53.3 |
|
52.0 |
|
53.2 |
|
52.0 |
| |
|
|
|
|
|
Shareholders’ equity |
|
164.2 |
|
194.5 |
|
164.3 |
|
194.5 |
| |
|
|
|
|
|
of which net result |
|
(44.8) |
|
(96.2) |
|
(44.9) |
|
(96.0) |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
| In millions of USD |
|
U.S. GAAP |
|
U.S. GAAP |
|
IFRS |
| |
Three months ended June 30,
|
|
Six months ended June 30,
|
|
Six months ended June 30,
|
| |
2023 |
|
2022 |
|
2023 |
|
2022 |
|
2023 |
|
2022 |
| |
|
|
|
|
|
|
|
Revenues |
|
2.3 |
|
1.5 |
|
4.5 |
|
4.1 |
|
4.5 |
|
4.1 |
| |
|
|
|
|
|
|
|
Research & Development |
|
(17.6) |
|
(18.6) |
|
(33.6) |
|
(30.8) |
|
(33.5) |
|
(30.7) |
| |
|
|
|
|
|
|
|
Sales & Marketing |
|
(0.5) |
|
(1.0) |
|
(1.0) |
|
(1.5) |
|
(1.0) |
|
(1.5) |
| |
|
|
|
|
|
|
|
General & Administrative |
|
(9.2) |
|
(5.7) |
|
(16.1) |
|
(12.3) |
|
(16.2) |
|
(12.2) |
| |
|
|
|
|
|
|
|
Operating expenses |
|
(27.3) |
|
(25.3) |
|
(50.7) |
|
(44.6) |
|
(50.7) |
|
(44.3) |
| |
|
|
|
|
|
|
|
Financial income/(expenses) |
|
0.8 |
|
0.8 |
|
1.4 |
|
0.9 |
|
1.4 |
|
0.8 |
| |
|
|
|
|
|
|
|
Income tax |
|
- |
|
- |
|
- |
|
- |
|
- |
|
- |
| |
|
|
|
|
|
|
|
Net loss |
|
(24.2) |
|
(23.0) |
|
(44.8) |
|
(39.6) |
|
(44.9) |
|
(39.5) |
| |
|
|
|
|
|
|
|
Basic/diluted net loss per share attributable to shareholders |
|
(0.26) |
|
(0.35) |
|
(0.48) |
|
(0.66) |
|
(0.48) |
|
(0.65) |
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW (unaudited)
|
|
|
|
|
|
|
|
|
| In millions of USD |
|
U.S. GAAP |
|
IFRS |
| |
Six months ended June 30,
|
|
Six months
ended June 30, |
| |
2023 |
|
2022 |
|
2023 |
|
2022 |
| |
|
|
|
|
|
Net cash flows provided / (used) in operating activities |
|
(46.4) |
|
(11.7) |
|
(45.4) |
|
(8.6) |
| |
|
|
|
|
|
Net cash flows provided / (used) in investing activities |
|
(0.3) |
|
(0.2) |
|
(0.3) |
|
(0.2) |
| |
|
|
|
|
|
Net cash flows provided / (used) in financing activities |
|
7.8 |
|
195.2 |
|
6.8 |
|
192.1 |
| |
|
|
|
|
|
Effect of exchange rate changes on cash & cash equivalents (U.S. GAAP presentation) |
|
3.7 |
|
(12.6) |
|
|
|
|
| |
|
|
|
|
|
Net increase / (decrease) in cash & cash equivalents |
|
(35.2) |
|
170.7 |
|
(38.9) |
|
183.3 |
| |
|
|
|
|
|
Net cash & cash equivalents at the beginning of the period |
|
209.2 |
|
77.3 |
|
209.2 |
|
77.3 |
| |
|
|
|
|
|
Effect of exchange rate changes on cash & cash equivalents (IFRS presentation) |
|
|
|
|
|
3.7 |
|
(12.6) |
| |
|
|
|
|
|
Net cash & cash equivalents at the end of the period |
|
174.0 |
|
248.0 |
|
174.0 |
|
248.0 |
About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology
platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, and is DBV Technologies’ method of delivering biologically active
compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV
Technologies’ food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are
traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market
(Ticker: DBVT).
Forward Looking Statements
This press release may contain forward-looking statements and estimates, including statements regarding DBV’s forecast of its cash runway,
designs of DBV’s anticipated clinical trials, DBV’s planned regulatory and clinical efforts including timing and results of communications with regulatory agencies, the ability of any of DBV’s product candidates, if approved, to
improve the lives of patients with food allergies, and the outcome of any litigation. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV’s product
candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development,
clinical trials and related regulatory reviews and approvals, including the impact of the COVID-19 pandemic, and DBV’s ability to successfully execute on its budget discipline measures. A further list and
description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV’s regulatory filings with the French Autorité
des Marchés Financiers (“AMF”), DBV’s filings and reports with the U.S. Securities and Exchange Commission (“SEC”), including in DBV’s Annual Report on Form 10-K for the
year ended December 31, 2022, filed with the SEC on March 2, 2023, and future filings and reports made with the AMF and SEC by DBV. Existing and prospective investors are cautioned not to place undue reliance on these
forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.
Investor Contact
Katie Matthews
DBV Technologies
+1 857-529-2563
katie.matthews@dbv-technologies.com
Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
angela.marcucci@dbv-technologies.com
Viaskin and EPIT are trademarks of DBV Technologies.
v3.23.2
Document and Entity Information
|
Jul. 31, 2023 |
| Document Information [Line Items] |
|
| Document Type |
8-K
|
| Document Period End Date |
Jul. 31, 2023
|
| Entity Registrant Name |
DBV Technologies S.A.
|
| Entity Incorporation, State or Country Code |
I0
|
| Entity File Number |
001-36697
|
| Entity Tax Identification Number |
00-0000000
|
| Entity Address, Address Line One |
177-181 avenue Pierre Brossolette
|
| Entity Address, Postal Zip Code |
92120
|
| Entity Address, City or Town |
Montrouge
|
| Entity Address, Country |
FR
|
| Country Region |
33
|
| City Area Code |
1
|
| Local Phone Number |
55 42 78 78
|
| Written Communications |
false
|
| Soliciting Material |
false
|
| Pre-commencement Tender Offer |
false
|
| Pre-commencement Issuer Tender Offer |
false
|
| Entity Emerging Growth Company |
false
|
| Amendment Flag |
false
|
| Entity Central Index Key |
0001613780
|
| Common Stock [Member] |
|
| Document Information [Line Items] |
|
| Title of 12(b) Security |
Ordinary shares, nominal value €0.10 per share
|
| No Trading Symbol Flag |
true
|
| Security Exchange Name |
NASDAQ
|
| American Depositary Share [Member] |
|
| Document Information [Line Items] |
|
| Title of 12(b) Security |
American Depositary Shares, each representing one- half of one ordinary share, nominal value €0.10 per share
|
| Security Exchange Name |
NASDAQ
|
| Trading Symbol |
DBVT
|
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionISO 3166-1 alpha-2 country code.
| Name: |
dei_EntityAddressCountry |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:countryCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true only for a security having no trading symbol.
| Name: |
dei_NoTradingSymbolFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:trueItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Details
| Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
| X |
- Details
| Name: |
us-gaap_StatementClassOfStockAxis=dei_AdrMember |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
DBV Technologies (NASDAQ:DBVT)
Historical Stock Chart
From Apr 2024 to May 2024
DBV Technologies (NASDAQ:DBVT)
Historical Stock Chart
From May 2023 to May 2024
